October 14, 2015
Eli Lilly and Company and Incyte Corporation: Positive Topline Results of RA-BEAM
Eli Lilly and Company and Incyte Corporation announced positive topline results of RA-BEAM, the fourth successful Phase 3 study of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis.